FDA’s decision to approve Barr Laboratories’ application for nonprescription sales of its emergency contraceptive Plan B to women ages 18 and older is “welcome news,” but it will not be “enough to overcome our nation’s stalled progress in reducing unintended pregnancies and the need for abortion,” Sharon Camp, president and CEO of the [click link for full article]